Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2017-12-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于2017年获得政府补助情况的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement listing government subsidies received by the company in 2017, including amounts, dates, and related approval numbers. It is a disclosure of government grants and subsidies rather than a financial report or earnings release. There is no indication of it being an annual report, interim report, earnings release, or any other financial statement. It is also not a regulatory certification or a report publication announcement. The document is a regulatory announcement about government subsidies received, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2017-12-29 Chinese
关于公司项目获国家重大新药创制科技重大专项立项支持的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about receiving government funding support for a specific research project related to a new drug. It details the project, the funding amount, and accounting treatment of the subsidy. There is no financial report, no detailed financial statements, no earnings data, no management discussion of results, nor any regulatory certification. The document is a regulatory announcement about a government grant and project status. It is short (930 characters) and does not contain financial statements or detailed financial analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2017-12-29 Chinese
关于签订募集资金四方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a four-party supervision agreement related to the management and use of funds raised through a non-public issuance of shares by the company. It details the amount raised, the opening of a special account for the funds, the parties involved, and the supervisory responsibilities. There are no financial statements or comprehensive financial performance data presented. The document is focused on capital raising and the regulatory compliance around the use of those funds, which fits the category of Capital/Financing Update rather than a full financial report or audit.
2017-12-24 Chinese
西南证券股份有限公司关于公司使用募集资金置换预先投入募集资金项目自筹资金情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from Southwest Securities Co., Ltd. regarding the use of raised funds by Puluo Pharmaceutical Co., Ltd. to replace self-raised funds previously invested in projects. It references regulatory guidelines and approvals related to the use of raised funds, details the amounts and projects involved, and includes an audit report from an accounting firm. The document is a specialized verification or audit opinion on the use of funds, not a full annual or interim financial report, earnings release, or capital update. It is not a simple announcement but a detailed verification report related to fundraising and fund usage compliance. This fits the category of an Audit Report / Information (AR), as it involves audit verification and compliance checking of fund usage, separate from a full annual report or financial statement filing. The document length is 2642 characters, which is relatively short but contains substantive audit and verification content, not just an announcement or certification letter. Therefore, the best classification is AR with high confidence. FY 2017
2017-12-21 Chinese
募集资金置换专项鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金置换专项鉴证报告" which translates to a "Special Verification Report on the Replacement of Raised Funds." It is issued by an accounting firm and includes a verification opinion on the company's management explanation regarding the replacement of self-raised funds with raised funds for investment projects. The document references regulatory guidelines related to the management and use of raised funds and includes detailed financial figures about the raised funds and their use. The document is a standalone audit/verification report focused on a specific financial activity (fund replacement) and does not constitute a full annual or interim report. It is not an announcement or a brief notice but a detailed verification report by auditors. The document length is 3658 characters, which is relatively short but contains substantive audit content. Therefore, it fits best under the category of Audit Report / Information (AR). Q4 2017
2017-12-21 Chinese
关于使用募集资金置换预先投入的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the use of raised funds to replace previously invested self-raised funds in investment projects. It details the approval by the board, supervisory board, independent directors, and the sponsor institution's verification. It references the non-public issuance of shares, the amount raised, and the specific use of funds, including replacement of self-raised funds with raised funds. The document is a formal disclosure about capital usage and financing activities, specifically about the replacement of self-raised funds with proceeds from a non-public share issuance. It does not contain financial statements or comprehensive financial data, nor is it a report or presentation. It is an update on capital structure and financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 3326 characters, which is consistent with an announcement rather than a full report.
2017-12-21 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.